Blocking PD-1 signaling has been found to enhance the overall function and abundance of ILC2s, leading to heightened anti-tumor effects within the TME [19], thus, it is crucial to investigate the specific subset of ILC2s that contributes to this anti-tumor functionality within the TME. This evidence concerns the gene PDCD1 and neoplasm.